Compound: protirelin
SMILES: O=C1N[C@H](C(=O)N[C@H](C(=O)N2[C@H](C(=O)N)CCC2)Cc3[nH]cnc3)CC1
InChIKey: XNSAINXGIQZQOO-SRVKXCTJSA-N
Synonyms: protirelin, 24305-27-9, Thyroliberin, Lopremone, Synthetic TRH, Rifathyroin, Thypinone, Thyrotropin-releasing factor, TSH-releasing factor, Protireline, Thyrotropic-releasing factor, 5-Oxo-L-prolyl-L-histidyl-L-prolinamide, ABBOTT-38579, Protirelinum, THYREL TRH, Synthetic tsh-releasing factor, Relefact TRH, Abbott 38579, Protirelin, synthetic, Protirelina, 5-oxo-pro-his-pro-nh2, L-Pyroglutamyl-L-histidyl-L-prolineamide, Protireline [INN-French], Protirelinum [INN-Latin], FDA 1725, L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-, Protirelina [INN-Spanish], CCRIS 2593, DTXSID0023533, Ro 8-6270/9, Relefact TRH (TN), Protirelin [USAN:INN:BAN:JAN], PROTIRELIN [INN], PROTIRELIN [JAN], EINECS 246-143-4, PROTIRELIN [USAN], (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide, PROTIRELIN [VANDF], 5Y5F15120W, NSC-760113, PROTIRELIN [MART.], PROTIRELIN [WHO-DD], L-Pyroglutamyl-L-histidinyl-L-prolinamide, DTXCID403533, PROTIRELIN [ORANGE BOOK], CHEBI:35940, PROTIRELIN [EP MONOGRAPH], A-38579, NSC 760113, Protireline (INN-French), Protirelinum (INN-Latin), Protirelina (INN-Spanish), PROTIRELIN (MART.), PROTIRELIN (EP MONOGRAPH), (2S)-N-[(2S)-1-[(2S)-2-aminocarbonylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxidanylidene-propan-2-yl]-5-oxidanylidene-pyrrolidine-2-carboxamide, pyroglutamyl-histidyl-prolylamide, Thyrotropin Releasing Factor, Trh-cambridge, TRH, Relefact, (2S)-N-((2S)-1-((2S)-2-aminocarbonylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxidanylidene-propan-2-yl)-5-oxidanylidene-pyrrolidine-2-carboxamide, (2S)-N-((2S)-1-((2S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide, Abbott38579, Thyroliberin TRH Merck, RefChem:870039, V04CJ02, Thyrotropin Releasing Hormone TRH, pyroGlu-His-Pro-NH2 (or 5-oxo-L-prolyl-L-histidyl-L-prolinamide), 246-143-4, Protirelin Acetate, L-Pyroglutamyl-L-histidyl-L-prolinamide, TRH, 117217-40-0, HOLO-TRANSFERRIN, C16H22N6O4, MFCD00038640, NCGC00160616-01, (S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-5-oxopyrrolidine-2-carboxamide, Synthetic TRF, Relefact-TRH, TRF, Thyrefact, Protirelin?, trh-sr, Protirelin CRS, UNII-5Y5F15120W, Human Transferrin, Stimu-TSH, Thyrotropin-releasing factor (pig), 24305-27-9 (free base), PR 546, PR-546, Synthetic thyrotropin-releasing factor, Pyr-His-Pro-NH2, D-His-Protirelin CRS, PyroGlu-His-prolinamide, TSH-RF, TRH [MI], CHEMBL1472, SCHEMBL33419, [3H]-TRH, GTPL2139, GTPL3836, orb1685534, SCHEMBL2182035, Siderophilin;partially saturated, pyroglutamyl-histidyl-prolinamide, Protirelin (JP18/USAN/INN), SCHEMBL19825647, [3H]TRH (human, mouse, rat), HY-P0002, Synthetic thyrotopin releasing factor, Tox21_111939, BDBM50072394, EBC-26800, s4680, AKOS015994636, AKOS040759052, CCG-268193, DB09421, FP33965, HS-2023, (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide, DA-64226, L-Pyroglutamyl-L-histidyl-L-proline amide, CAS-24305-27-9, NS00006015, C03958, C74244, D00176, Prolinamide, 5-oxo-L-prolyl-L-histidyl-, L-, L-PYROGLUTAMYL-L-HISTIDYL-L-PROLINE-AMIDE, (Pyro)-L-glutamic acid-L-histidine-L-proline-NH2, EN300-27034140, Q24726011, Prolinamide, 1-[N-(5-oxo-L-prolyl)-L-histidyl]-, L-, (2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanoyl]pyrrolidine-2-carboxamide, (2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-(1H-imidazol-5-ylmethyl)-2-oxo-ethyl]-5-oxo-pyrrolidine-2-carboxamide, (2S)-N-[(1S)-2-[(2S)-2-carbamoylpyrrolidino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]-5-keto-pyrrolidine-2-carboxamide, 1-(3-(1H-Imidazol-5-yl)-2-([(5-oxo-2-pyrrolidinyl)carbonyl]amino)propanoyl)-2-pyrrolidinecarboxamide #, 1-[3-(1H-4-imidazolyl)-2-(5-oxotetrahydro-1H-2-pyrrolylcarboxamido)propanoyl]tetrahydro-1H-2-pyrrolecarboxamide, 2-Pyrrolidinecarboxamide, N-[1-[(2-carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-,, 2-Pyrrolidinecarboxamide, N-[1-[(2-Carbamoyl-1-pyrrolidinyl)carbonyl]-2-imidazol-4-ylethyl]-5-oxo-, (S,S,S)-
Theoretical properties:
molecular_formula: C16H22N6O4
molecular_weight: 362.38 g/mol
exact_mass: 362.17025320 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 6
heavy_atom_count: 26
topological_polar_surface_area: 150 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Protirelin is a tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence. It has a role as a human metabolite. It is a peptide hormone and a tripeptide.
chebi: A tripeptide composed of <small>L</small>-pyroglutamyl, <small>L</small>-histidyl and <small>L</small>-prolinamide residues joined in sequence.
chembl: PROTIRELIN is a protein listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Thyrotropin-releasing hormone (TRH) is a hypophysiotropic hormone produced by neurons in the hypothalamus that stimulates the release of thyroid-stimulating hormone (TSH) as well as prolactin from the anterior pituitary.
TRH has been used clinically in diagnosis of hyperthyroidism, and for the treatment of spinocerebellar degeneration and disturbance of consciousness in humans. Its pharmaceutical form is called protirelin (INN) ().